In the current view of our study, the successful acquisition of prognostic signatures based on four anoikis-related lncRNAs has important clinical meanings and offers potentially novel therapeutic targets for eliminating resistance to BRAF-targeted inhibitors, MEK-targeted inhibitors, and immunotherapy in cutaneous melanoma, but limitations remain. The gene discussed is MAP2K7; the disease is cutaneous melanoma.